Abstract Current guidelines recommend use of the aldosterone-renin ratio (ARR) for the case detection of primary aldosteronism (PA), the most common cause of secondary hypertension, in selected hypertensive patients. ''Confirmatory'' tests are then recommended in patients who tested positive at the ARR to exclude from further diagnostic work-up false positive results. Based on our experience we hypothesized that the ARR carries quantitative information, which can avoid the need of confirmatory tests. We herein describe a study protocol to identify the ARR cut-off value with a high specificity for the exclusion of aldosterone-producing adenoma (APA) based on analysis of two large prospectively collected datasets of patients in which a conclusive diagnosis of APA was made by the four corners criteria. This will also serve to investigate the diagnostic gain provided over this ARR cut-off value by one confirmatory test, the captopril challenge test. Hence, with this protocol we expect to identify an ARR cut-off value that might prevent further testing in patients with either a low or a high probability of APA. This could translate in a higher diagnostic accuracy and, by preventing unnecessary invasive testing, into a substantial saving of money, time, and resources.
Introduction
The current guidelines recommend the use of the aldosterone-renin ratio (ARR) for the screening of primary aldosteronism (PA), the most common endocrine cause of secondary arterial hypertension [1] [2] [3] . To this end the use of liberal cut-off values for the ARR is usually exploited to maximize sensitivity, even though it carries the burden of a low specificity. Accordingly, confirmatory tests are advised in order to identify and exclude from further costly testing false positive results. The subtyping of PA, in fact, requires adrenal vein sampling (AVS), a minimally invasive, costly, and not widely available procedure [1, 3, 4] . We postulated that the ARR value carries important quantitative information, which, if taken into proper consideration, might render the use of exclusion tests not necessary when high or very high ARR values are detected. Therefore, a careful selection of the ARR cut-offs can prevent the use of confirmatory tests and assist physicians in the clinical decision-making. Moreover, the confirmatory tests are being used based on the unproven premises that PA is consistently autonomous from the renin-angiotensin system (RAS) [4] . Unfortunately, this autonomy does not occur in real life, as shown by the prospective evaluation of two such tests, the saline infusion and the captopril challenge, in the PAPY study [5, 6] . Hence, use of these tests likely lends to identification of only the subsets of PA that are autonomous from the RAS. Moreover, at the rate of prevalence commonly seen even at referral centers, e.g. between 11.2 and 14 %, these tests exhibit a negative predictive value much higher than their positive predictive value, indicating that they work as exclusion rather than as confirmatory tests [6] .
Accordingly, taking advantage of two prospectively collected large datasets, in which the conclusive diagnosis of PA due to aldosterone-producing adenoma (APA) was available as reference [7] , we set up this study to answer the following questions: (1) Is there a cut-off value of the ARR providing such a trivial false positive rate for the diagnosis of APA that renders confirmatory tests useless and by itself mandates AVS? (2) Does performing the captopril challenge test provide any diagnostic gain, once an ARR either above or below the cut-off values that maximize overall accuracy, e.g. sensitivity and specificity, has been chosen?
Our purpose is herein to describe the design of the study according to the recommendations of the STARD guidelines [7] .
Methods
The AQUARR study will include two prospectively recruited cohorts of hypertensive patients. For both studies the protocol (Fig. 1) was approved by the ethical committee of the University of Padua and an informed written consent was obtained from each participant.
Exploratory Dataset
The first cohort will be used for exploratory purposes and entails the Primary Aldosteronism Prevalence in Hypertensives (PAPY) study dataset [8] . The design of this study was already published and therefore will be only briefly recalled here. The PAPY study was an Italian multicenter observational prospective study, which enrolled 1125 consecutive patients with hypertension (HT) diagnosis within the previous six months, referred by their family doctor to specialized centers for the diagnosis and treatment of HT. The only exclusion criteria were a prior diagnosis of any secondary form of HT and the patient's refusal to participate in the study. The inclusion criterion entailed a diagnosis of HT confirmed by office blood pressure measurement by mercury sphygmomanometer according to guidelines [9] .
After enrolment patients treated only with either a longacting calcium channel blocker and/or doxazosin underwent a screening test without any change of medications. Patients on therapies including medications different from those mentioned above were switched to calcium channels blockers and/or doxazosin before the screening test for the following duration: treatment with mineralocorticoid receptor antagonists (spironolactone, canrenone, or potassium canreonate) was withdrawn for at least 6 weeks; therapy with other agents, including diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin II type 1 receptor antagonists, was withdrawn for at least 2 weeks.
The screening test was carried out after an overnight fast and 1 hour quiet rest in the sitting position, between 7 AM and 9 AM with Na ? and K ? , plasma renin activity (PRA), aldosterone, and cortisol measured at baseline and again 60 min after captopril administration (50 mg orally). The aldosterone (in ng/dl)/PRA (in ng/ml/h) ratio, at baseline and after captopril, and a score estimating the probability of PA based on a validated multivariate logistic discriminant analysis (LDF) score [10] were calculated.
All patients with baseline ARR C40 and after captopril ARR C30, or an LDF score C0.50 underwent a high-resolution computed tomography (CT) scan with 3-mm slices
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Choice of the cut-off value that maximized accuracy CharacterisƟcs (ROC) curve analysis of the ARR for the exclusion of APA Fig. 1 Flow-chart of the study thickness and systematic use of a contrast medium, and/or magnetic resonance (MR) imaging. Adrenal vein sampling [11] at the centers where it was available, was performed in all those submitted to CT and/or MR. Only bilaterally selective AVS was judged to provide an accurate diagnosis. The criteria for considering AVS selective and for lateralization of aldosterone secretion were previously established as described in detail [11] . Dexamethasonesuppressed adrenocortical 131 I-norcholesterol scintigraphy [12] was used to show a lateralized aldosterone excess production whenever AVS was unavailable.
Plasma renin activity was measured by radioimmunoassay with commercial kits (Ren CTK, Sorin Biomedica Saluggia, Italy, in 10 centers; or Angiotensin I RIA CT, Radim, Pomezia, Italy, in the remainder). For both kits, the intra-assay and inter-assay coefficient of variation was within 8 and 10 %. Normal range sitting, at rest, and on a normal Na ? diet was 0.65 to 2.64 ng/ml/h. The assay for aldosterone was performed with a commercial kit (Aldosterone Mirya, Techogenetics, Cassina de Pecchi, Italy). Normal range was 10 to 150 pg/ml supine and 30 to 320 pg/ml upright on a normal Na ? diet; both intra-assay and inter-assay coefficients of variation for this assay were \5.6 %; the cross-reactivity of the antibody for aldosterone for the other adrenal steroids was \0.001 %. Data were analyzed without adjustment for centers as a survey of hormone values showed no evidence for heterogeneity across centers.
The PA diagnosis required evidence of autonomous excess aldosterone production, which was defined as an ARR C40 at baseline plus an ARR C30 after captopril, or a logistic discriminant function C0.50 [10, 13] . For the calculation of the ARR the PRA values \0.2 ng/ml/h were arbitrarily set to 0.2. On completion of the diagnostic workup an Adjudication Committee was responsible for determining whether patients had PA or not. Moreover, the diagnosis of APA required the four corners criteria: (1) lateralization of aldosterone secretion at AVS, or evidence of lateralized uptake of 131 I-norcholesterol at dexamethasone-suppressed adrenocortical scintigraphy, (2) surgery, (3) pathology, and (4) outcome of adrenalectomy at followup as assessed by the demonstration of normokalemia and cure or improvement of HT at least 120 days after adrenalectomy. Cure was defined as a systolic blood pressure \140 mmHg and diastolic blood pressure \90 mmHg without medications; improvement as a systolic and diastolic blood pressure \140/90 mmHg, respectively, on the same or a reduced number of medications and/or a reduced number of defined daily doses [14] . Patients with a biochemical diagnosis of PA, but without evidence of a lateralized aldosterone excess, were held to have idiopathic hyperaldosteronism.
Validation Cohort
The second cohort to be used for validation purposes will entail consecutive prospectively recruited Caucasian patients with HT referred to the Hypertension Center Outpatient Facility of the University of Padua between January 2012 and December 2014.
Patients with a new diagnosis of HT who were never screened for secondary HT in the 5 years before, with either grade II/III HT, or resistant HT, hypokalemia, or incidentaloma, underwent basal and after captopril PRA and aldosterone measurements, as described above according to current guidelines [1] . All these tests were carried out in our center under carefully standardized conditions and pharmacologic preparation as described above, with the only variation that the minimum wash-out period was 4 weeks for patients on diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin II type 1 receptor antagonists. Patients were excluded from the study if they underwent testing while on potentially interfering treatment.
Plasma renin activity and aldosterone concentration were measured using commercial kits after 1 h in the supine position and again 45 min after administration of 50 mg captopril. Serum levels and 24-hour urinary excretion of Na ? and K ? were measured with standardized procedures. All biochemical measurements were performed in an ISO 9001 certified laboratory; normal values and within-and inter-assay coefficient of variation have been reported [8, 15] .
Besides the impossibility to switch patients to the appropriate medications, exclusion criteria entailed a previous diagnosis of secondary HT and the diagnosis of secondary HT after the interpretation of screening tests.
Primary aldosteronism was diagnosed following guidelines [1] and based on the criteria set up in the PAPY study [10, 13] . Aldosterone-producing adenoma was diagnosed as already reported by the aforementioned 4 corners criteria.
Data were prospectively gathered with a predefined form by a physician and included: demographic data, medication data, serum sodium, potassium, creatinine, 24 h sodium and potassium urinary excretion, and microalbuminuria.
Statistical Analysis
Quantitative variables will be examined after achievement of a Gaussian distribution by log or square root transformation, as appropriate. One-way ANOVA followed by Bonferroni's post hoc test or t-test will be used to compare quantitative variables between groups. The distribution of categorical variables will be investigated by Chi square analysis.
Based on the premise that conclusive diagnosis of the subtype of PA is clearly feasible for APA by using the 4 corners criteria (and also for the very rare Familial Hyperaldosteronism (FH)-1 by genetic testing [16] ), following the STARD recommendations [7] we decided beforehand to use this diagnosis as reference for determining the operative features of the ARR and identifying the optimal cut-off values.
The sensitivity, specificity, and accuracy of each test will be calculated. The diagnostic odds ratio, that is the odds of positivity among diseased patients divided by the odds of negativity among non-diseased patients, will be also used to estimate the diagnostic accuracy [17] . The area under the receiver operating characteristics (ROC) curve will be used to measure and compare the accuracy of the tests [18] for prediction of the conclusive diagnosis of APA or not. The Youden Index (YI) (=max (c) [sensitivity (c) ? specificity (c) -1]) will be used to identify the basal and after captopril ARR threshold values corresponding to the value of the ROC curve farthest from the identity line. This value corresponds to the optimal cut-off, defined as the value with the highest combination of sensitivity and specificity.
To identify the cut-off value of the ARR that provided low false negative and positive rates for the diagnosis of APA, we will analyze the PAPY dataset based on predefined thresholds, with 1 % decreases from 5 to 1 %. The results obtained will be confirmed in the validation cohort. To determine if the captopril challenge test furnishes any diagnostic gain over the cut-off value, which maximized overall accuracy, ARR ROC curve analysis will be performed on the post-captopril and compared to the baseline ARR ROC curve.
Significance will be set at p \ 0.05. The MedCalc (version 8.1.1.0, MedCalc Software, Mariakerke, Belgium) and SPSS (version 22 for Mac, IBM, USA) software will be used for these purposes.
Discussion and Expected Results
Based on current guidelines, the screening of PA is carried out using the ARR to maximize the sensitivity. Confirmatory/exclusion tests are advised in order to exclude false positive results from further testing [1] [2] [3] . This is regarded as a key step in that AVS, which is required for PA subtyping, is costly and not widely available [1, 3, 4] .
Based on our long-standing experience we realized that the ARR value carries important quantitative information, which might render unnecessary the use of exclusion tests when the ARR values exceed a predetermined carefully chosen cut-off value. By analyzing two large datasets of prospectively recruited hypertensive patients who were screened in a similar standardized way, we expect to be able to identify this value, which might allow avoiding further testing in the patients with a low or high probability of APA. We anticipate that this will translate in a higher diagnostic accuracy because in the PAPY study the prospective evaluation of exclusion tests, such as the saline infusion and the captopril challenge [5, 6] , demonstrated the fallacy of considering APA as consistently autonomous from the RAS. This unproven premise [4] , therefore, likely lends to identification of only the APA subsets that are autonomous from the RAS. Furthermore, given the current times of economic hardship unnecessary testing is crucially important.
Finally, our perception is that the use of confirmatory/ exclusion testing in patients with high post-test probability of APA, as identified by ARR values exceeding a predefined cut-off, could be unnecessary, if not confounding. According to Bayesian theorem, in patients with ARR values above such predefined cut-off value, entailing a cohort with a prevalence of APA much higher than 50 %, a negative confirmatory/exclusion test would decrease the post-test probability of disease only slightly, thus not preventing clinicians from ordering further expensive testing.
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